search
Back to results

Efficacy of CPPLAI in Laparoscopic Sleeve Gastrectomy Patients (CPPLAI)

Primary Purpose

Obesity, Morbid, Pain, Postoperative

Status
Completed
Phase
Not Applicable
Locations
Saudi Arabia
Study Type
Interventional
Intervention
CPPLAI
Placebo
Bupivacaine 0.25%
Sponsored by
King Khalid University Hospital
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional prevention trial for Obesity, Morbid focused on measuring Laparoscopic sleeve gastrectomy, post operative pain, local anesthetic infiltration, Periportal, Preperitoneal, Morbid obesity

Eligibility Criteria

16 Years - 60 Years (Child, Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • American Society of Anesthesiologist (ASA) physical status I-III
  • Age 18-60 years
  • Either gender
  • Obese patients (BMI >35 for laparoscopic sleeve gastrectomy

Exclusion Criteria:

  • American Society of Anesthesiologist (ASA) physical status IV
  • Patients uncontrolled HTN
  • Anticipated difficult intubation
  • Allergic to morphine
  • Clinically significant neurological, cardiovascular, renal hepatic disease planned for postoperative surgical intensive care (SICU) admission
  • History of drug abuse or chronic opioid use

Sites / Locations

  • King Khalid University Hospital

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Placebo Comparator

Arm Label

CPPLAI

Placebo

Arm Description

Group-1 (CPPLAI) (n= 59) will receive intraoperative combined periportal and preperitoneal bupivacaine 0.25% 2-3 mg/kg diluted in 40 ml normal saline in patients scheduled for laparoscopic sleeve gastrectomy.

Group 2 (placebo) (n= 58) will receive intraoperative combined periportal and preperitoneal sterile water 40 ml in patients scheduled for laparoscopic sleeve gastrectomy.

Outcomes

Primary Outcome Measures

Postoperative pain
Pain will be measured postoperatively using numerical rating scale (NRS) from 0 to 10 after laparoscopic sleeve gastrectomy. Where 0 is no pain and 10 is worst pain imaginable.

Secondary Outcome Measures

Postoperative Morphine consumption
Postoperative intravenous Morphine consumption in milligrams will be calculated as a total dose per patient that received to control pain after laparoscopic sleeve gastrectomy.
Length of hospital stay
Total number of days the patient stay in the hospital

Full Information

First Posted
December 8, 2020
Last Updated
October 2, 2023
Sponsor
King Khalid University Hospital
search

1. Study Identification

Unique Protocol Identification Number
NCT04680923
Brief Title
Efficacy of CPPLAI in Laparoscopic Sleeve Gastrectomy Patients
Acronym
CPPLAI
Official Title
Efficacy of Combined Periportal and Preperitoneal Local Anesthetic Infiltration (CPPLAI) in Laparoscopic Sleeve Gastrectomy Patients
Study Type
Interventional

2. Study Status

Record Verification Date
October 2023
Overall Recruitment Status
Completed
Study Start Date
December 8, 2020 (Actual)
Primary Completion Date
June 7, 2021 (Actual)
Study Completion Date
July 7, 2021 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
King Khalid University Hospital

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
The high demand for bariatric surgery due to the increasing prevalence of obesity worldwide necessitate evidence-based clinical pathway such as Enhanced Recovery After Bariatric Surgery (ERABS). The paradigm of surgery has been shifted from open to laparoscopic in morbidly obese patients. Laparoscopic Sleeve Gastrectomy (LSG) is the most common procedure performed in our institute for sustained weight loss and amelioration of obesity-related comorbidities. Pain control in ERABS is one of the key factors for improved outcomes. Surgery induced acute postoperative pain, stress response and fatigue lead to prolonged convalescence and hospital stay. Optimal titrated safe postoperative pain management in LSG patients still remains a challenge.
Detailed Description
Obesity is a complex multifactorial disease. The worldwide prevalence of obesity has doubled since 1980 to a level that now almost a third of the world's population is classified as overweight. Laparoscopic Sleeve Gastrectomy (LSG) is one of the effective treatments for sustained weight loss and to ameliorate the obesity-related comorbidities, and now the most commonly performed bariatric surgery worldwide. Postoperative pain from the laparoscopic portal sites and the visceral pain after gastrectomy requires a multimodal approach for pain management. As obese patients are sensitive to opioids overdose and at risk of respiratory depression and obstructive sleep apnoea, local anesthetic infiltration at the surgical incision sites and preperitoneal can decrease postoperative opioid consumption after LSG. Perioperative multimodal analgesia uses combinations of analgesic medications that act on different sites and pathways in an additive or synergistic manner to achieve pain relief with minimal or no opiate consumption. Although all medications have side effects, opiates have particularly concerning, multisystemic, long-term, and short-term side effects, which increase morbidity and prolong admissions. local infiltration analgesia (LIA) used widely as an effective component of multimodal analgesia and represents valuable options for controlling perioperative pain. LIA involves the injection and/or infusion of a local anesthetic near the site of surgical incision to provide targeted analgesia. A wide variety of techniques have been described, including single-injection intraoperative wound infiltration, indwelling wound infusion catheters, and the recent high-volume LIA technique associated with joint replacement surgery. Although, preperitoneal local anesthetic infiltration is a novel technique that was first described for pain relief after laparoscopic hernia repair. Recently, the investigators have used this technique in our institute during laparoscopic hernia repair which is now gaining popularity worldwide. Another investigator reported that continuous preperitoneal analgesia better attenuated postoperative inflammatory response and provided comparable overall analgesia to that with continuous epidural analgesia following radical cystectomy. Recently, a large systematic review and meta-analysis comparing preperitoneal or subcutaneous wound catheters with epidural analgesia in abdominal surgery showed preperitoneal wound catheters are an effective pain modality in abdominal surgery. Pain control was as effective as epidural analgesia and recovery parameters, opioid consumption, the incidence of hypotension, and patient satisfaction seemed to be in favor of preperitoneal wound catheters compared with active alternatives, as well as placebo. The trend for bariatric surgery is now moving towards opiates-almost free anesthesia. Since the first description of preperitoneal local anesthetic infiltration almost 2 decades ago little work has been done to test its efficacy, especially in LSG patients. The investigators of this study hypothesis that CPPLAI is an effective technique to reduce postoperative pain and favors early mobilization and patient satisfaction due to its fewer side effects.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Obesity, Morbid, Pain, Postoperative
Keywords
Laparoscopic sleeve gastrectomy, post operative pain, local anesthetic infiltration, Periportal, Preperitoneal, Morbid obesity

7. Study Design

Primary Purpose
Prevention
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Model Description
117 adult patients scheduled for Laparoscopic Sleeve Gastrectomy (LSG) will be recruited in this prospective clinical study. The patients will be divided into two groups; group-1 (CPPLAI) (n= 59) will receive intraoperative combined periportal and preperitoneal bupivacaine 0.25% 2-3 mg/kg diluted in 40 ml normal saline and group 2 (placebo) (n= 58) periportal and preperitoneal 40 ml of sterile water will be injected.
Masking
ParticipantCare ProviderOutcomes Assessor
Masking Description
All patients, care providers in PACU & ward (nurses), and outcome assessors (assistant anesthesiologist) will be blinded to the group allocation. Only the assigned anesthesiologist responsible for perioperative care and the surgeon performing preperitoneal local anesthetic infiltration will be aware of the group allocation to treat any unwanted side effects during and after the operation.
Allocation
Randomized
Enrollment
120 (Actual)

8. Arms, Groups, and Interventions

Arm Title
CPPLAI
Arm Type
Experimental
Arm Description
Group-1 (CPPLAI) (n= 59) will receive intraoperative combined periportal and preperitoneal bupivacaine 0.25% 2-3 mg/kg diluted in 40 ml normal saline in patients scheduled for laparoscopic sleeve gastrectomy.
Arm Title
Placebo
Arm Type
Placebo Comparator
Arm Description
Group 2 (placebo) (n= 58) will receive intraoperative combined periportal and preperitoneal sterile water 40 ml in patients scheduled for laparoscopic sleeve gastrectomy.
Intervention Type
Procedure
Intervention Name(s)
CPPLAI
Other Intervention Name(s)
Bupivacaine 0.25%
Intervention Description
In this intervention, after general anesthesia patients will receive intraoperative combined periportal and preperitoneal bupivacaine 0.25% 2-3 mg/kg diluted in 40 ml normal saline.
Intervention Type
Other
Intervention Name(s)
Placebo
Other Intervention Name(s)
Sterile water
Intervention Description
In this intervention, after general anesthesia patients will receive intraoperative combined periportal and preperitoneal 40 ml of sterile water.
Intervention Type
Drug
Intervention Name(s)
Bupivacaine 0.25%
Other Intervention Name(s)
CPPLAI
Intervention Description
In this intervention, after general anesthesia patients will receive intraoperative combined periportal and preperitoneal bupivacaine 0.25% 2-3 mg/kg diluted in 40 ml normal saline.
Primary Outcome Measure Information:
Title
Postoperative pain
Description
Pain will be measured postoperatively using numerical rating scale (NRS) from 0 to 10 after laparoscopic sleeve gastrectomy. Where 0 is no pain and 10 is worst pain imaginable.
Time Frame
From preoperative to day two postoperative
Secondary Outcome Measure Information:
Title
Postoperative Morphine consumption
Description
Postoperative intravenous Morphine consumption in milligrams will be calculated as a total dose per patient that received to control pain after laparoscopic sleeve gastrectomy.
Time Frame
From preoperative to day two postoperative
Title
Length of hospital stay
Description
Total number of days the patient stay in the hospital
Time Frame
Through study completion, an average of 2 days.

10. Eligibility

Sex
All
Minimum Age & Unit of Time
16 Years
Maximum Age & Unit of Time
60 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: American Society of Anesthesiologist (ASA) physical status I-III Age 18-60 years Either gender Obese patients (BMI >35 for laparoscopic sleeve gastrectomy Exclusion Criteria: American Society of Anesthesiologist (ASA) physical status IV Patients uncontrolled HTN Anticipated difficult intubation Allergic to morphine Clinically significant neurological, cardiovascular, renal hepatic disease planned for postoperative surgical intensive care (SICU) admission History of drug abuse or chronic opioid use
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Abdul Sattar Narejo, FCPS
Organizational Affiliation
King Khalid University Hospital
Official's Role
Principal Investigator
Facility Information:
Facility Name
King Khalid University Hospital
City
Riyadh
ZIP/Postal Code
7805/11472
Country
Saudi Arabia

12. IPD Sharing Statement

Plan to Share IPD
Yes
IPD Sharing Plan Description
After completing the data collection by July 2021, Pain score, opioid consumption, and length of hospital stay will be shared.
IPD Sharing Time Frame
December 2021
IPD Sharing Access Criteria
IPD (protocol, statistical analysis) will be shared on submitting requests through email to the principal investigator.
Citations:
PubMed Identifier
30253139
Citation
Chooi YC, Ding C, Magkos F. The epidemiology of obesity. Metabolism. 2019 Mar;92:6-10. doi: 10.1016/j.metabol.2018.09.005. Epub 2018 Sep 22.
Results Reference
background
PubMed Identifier
30004814
Citation
Chung AY, Thompson R, Overby DW, Duke MC, Farrell TM. Sleeve Gastrectomy: Surgical Tips. J Laparoendosc Adv Surg Tech A. 2018 Aug;28(8):930-937. doi: 10.1089/lap.2018.0392. Epub 2018 Jul 13.
Results Reference
background
PubMed Identifier
31256367
Citation
Belcaid I, Eipe N. Perioperative Pain Management in Morbid Obesity. Drugs. 2019 Jul;79(11):1163-1175. doi: 10.1007/s40265-019-01156-3.
Results Reference
background
PubMed Identifier
29926357
Citation
Boerboom SL, de Haes A, Vd Wetering L, Aarts EO, Janssen IMC, Geurts JW, Kamphuis ET. Preperitoneal Bupivacaine Infiltration Reduces Postoperative Opioid Consumption, Acute Pain, and Chronic Postsurgical Pain After Bariatric Surgery: a Randomized Controlled Trial. Obes Surg. 2018 Oct;28(10):3102-3110. doi: 10.1007/s11695-018-3341-6.
Results Reference
background
PubMed Identifier
28526156
Citation
Beverly A, Kaye AD, Ljungqvist O, Urman RD. Essential Elements of Multimodal Analgesia in Enhanced Recovery After Surgery (ERAS) Guidelines. Anesthesiol Clin. 2017 Jun;35(2):e115-e143. doi: 10.1016/j.anclin.2017.01.018.
Results Reference
background
PubMed Identifier
24815966
Citation
Merritt CK, Mariano ER, Kaye AD, Lissauer J, Mancuso K, Prabhakar A, Urman RD. Peripheral nerve catheters and local anesthetic infiltration in perioperative analgesia. Best Pract Res Clin Anaesthesiol. 2014 Mar;28(1):41-57. doi: 10.1016/j.bpa.2014.02.002. Epub 2014 Mar 18.
Results Reference
background
PubMed Identifier
31785717
Citation
Joshi GP, Machi A. Surgical site infiltration: A neuroanatomical approach. Best Pract Res Clin Anaesthesiol. 2019 Sep;33(3):317-324. doi: 10.1016/j.bpa.2019.07.017. Epub 2019 Jul 25.
Results Reference
background
PubMed Identifier
9692587
Citation
Deans GT, Wilson MS, Brough WA. Controlled trial of preperitoneal local anaesthetic for reducing pain following laparoscopic hernia repair. Br J Surg. 1998 Jul;85(7):1013-4. doi: 10.1046/j.1365-2168.1998.00763.x.
Results Reference
background
PubMed Identifier
28442949
Citation
Aldohayan A, Eldawlatly A. Combined preincisional periportal and preperitoneal infiltration with bupivacaine in pain relief after laparoscopic surgery. Saudi J Anaesth. 2017 Apr-Jun;11(2):135-136. doi: 10.4103/sja.SJA_153_17. No abstract available.
Results Reference
background
PubMed Identifier
30829734
Citation
Othman AH, Ahmed DG, Abd El-Rahman AM, El Sherif FA, Mansour S, Aboeleuon E. Effect of Preperitoneal Versus Epidural Analgesia on Postoperative Inflammatory Response and Pain Following Radical Cystectomy: A Prospective, Randomized Trial. Clin J Pain. 2019 Apr;35(4):328-334. doi: 10.1097/AJP.0000000000000679.
Results Reference
background
PubMed Identifier
29781846
Citation
Mungroop TH, Bond MJ, Lirk P, Busch OR, Hollmann MW, Veelo DP, Besselink MG. Preperitoneal or Subcutaneous Wound Catheters as Alternative for Epidural Analgesia in Abdominal Surgery: A Systematic Review and Meta-analysis. Ann Surg. 2019 Feb;269(2):252-260. doi: 10.1097/SLA.0000000000002817.
Results Reference
background
PubMed Identifier
30817360
Citation
Lirk P, Rathmell JP. Opioid-free anaesthesia: Con: it is too early to adopt opioid-free anaesthesia today. Eur J Anaesthesiol. 2019 Apr;36(4):250-254. doi: 10.1097/EJA.0000000000000965. No abstract available.
Results Reference
background

Learn more about this trial

Efficacy of CPPLAI in Laparoscopic Sleeve Gastrectomy Patients

We'll reach out to this number within 24 hrs